Keyword Analysis & Research: somekawa kohei


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
somekawa kohei1.280.337108214
somekawa1.20.65944148
kohei1.350.43584985

Keyword Research: People who searched somekawa kohei also searched

Keyword CPC PCC Volume Score
somekawa kohei1.690.9240120

Search Results related to somekawa kohei on Search Engine

  • Adverse events induced by nivolumab and ipilimumab …

    sagepub.com

    https://journals.sagepub.com/doi/full/10.1177/17588359211058393

    WEBFeb 11, 2022 · First published online February 11, 2022. Adverse events induced by nivolumab and ipilimumab combination regimens. Kohei Somekawa, Nobuyuki Horita https://orcid.org/0000-0002-8200-0340, …

    DA: 84 PA: 69 MOZ Rank: 31

  • Adverse events induced by nivolumab and ipilimumab …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/35173819/

    WEBFeb 11, 2022 · PMID: 35173819. PMCID: PMC8841925. DOI: 10.1177/17588359211058393. Abstract. Background: No meta-analysis has assessed the pooled frequencies of …

    DA: 95 PA: 10 MOZ Rank: 11

  • Adverse events induced by nivolumab and ipilimumab …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841925/

    WEBFeb 11, 2022 · Kohei Somekawa, Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Nobuyuki Horita, Department of … DOI: 10.1177/17588359211058393 Published: 2022

    DOI: 10.1177/17588359211058393

    Published: 2022

    DA: 2 PA: 44 MOZ Rank: 46

  • Adverse events induced by nivolumab and ipilimumab …

    sagepub.com

    https://journals.sagepub.com/doi/abs/10.1177/17588359211058393

    WEBFeb 11, 2022 · Adverse events induced by nivolumab and ipilimumab combination regimens - Kohei Somekawa, Nobuyuki Horita, Ayami Kaneko, Yoichi Tagami, Nobuhiko …

    DA: 86 PA: 84 MOZ Rank: 3

  • Adverse events induced by durvalumab and …

    sagepub.com

    https://journals.sagepub.com/doi/abs/10.1177/17588359231198453

    WEBSep 13, 2023 · Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis - Hiromi Matsumoto, Kohei …

    DA: 76 PA: 38 MOZ Rank: 54

  • (PDF) Adverse events induced by durvalumab and

    researchgate.net

    https://www.researchgate.net/publication/373920939_Adverse_events_induced_by_durvalumab_and_tremelimumab_combination_regimens_a_systematic_review_and_meta-analysis

    WEBSep 13, 2023 · Kohei Somekawa. Nobuyuki Horita. Yokohama City University. Suguru Ueda. Show all 18 authors. Download full-text PDF. References (16) Figures (5) Abstract …

    DA: 4 PA: 53 MOZ Rank: 87

  • Adverse events induced by nivolumab and ipilimumab

    researchgate.net

    https://www.researchgate.net/publication/358555538_Adverse_events_induced_by_nivolumab_and_ipilimumab_combination_regimens

    WEBFeb 11, 2022 · Therapeutic Advances in Medical Oncology 14:175883592110583. DOI: 10.1177/17588359211058393. License. CC BY-NC 4.0. Authors: Kohei Somekawa. Nobuyuki Horita. Yokohama City …

    DA: 30 PA: 10 MOZ Rank: 71

  • Pembrolizumab monotherapy versus pembrolizumab …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758435/

    WEBDec 5, 2021 · Matsumoto H, Kobayashi N, Somekawa K, Fukuda N, Kaneko A, Kamimaki C, et al. Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in …

    DA: 12 PA: 27 MOZ Rank: 24

  • Aetiological agents of adult community-acquired …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/37751988/

    WEBPMID: 37751988. PMCID: PMC10533802. DOI: 10.1136/bmjresp-2023-001800. Abstract. Objective: Epidemiological information is essential in providing appropriate empiric …

    DA: 39 PA: 87 MOZ Rank: 99